These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

782 related items for PubMed ID: 29605015

  • 1. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M, Gabriels J, Khan M, Shaban N, D'Amato S, Liu CF, Markowitz SM, Ip JE, Thomas G, Singh P, Lerman B, Patel A, Cheung JW.
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [Abstract] [Full Text] [Related]

  • 2. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A, Lin T, Plesman J, Heeger CH, Lemes C, Metzner A, Mathew S, Wissner E, Wohlmuth P, Ouyang F, Kuck KH, Tilz RR.
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [Abstract] [Full Text] [Related]

  • 3. Left atrial thrombus despite continuous direct oral anticoagulant or warfarin therapy in patients with atrial fibrillation: insights into rates and timing of thrombus resolution.
    Wu MS, Gabriels J, Khan M, Shaban N, D'Amato SA, Liu CF, Markowitz SM, Ip JE, Thomas G, Singh P, Lerman BB, Patel A, Cheung JW.
    J Interv Card Electrophysiol; 2018 Nov; 53(2):159-167. PubMed ID: 30078133
    [Abstract] [Full Text] [Related]

  • 4. Comparison of different oral anticoagulant regimens in patients with atrial fibrillation undergoing ablation or cardioversion.
    Gawałko M, Kapłon-Cieślicka A, Budnik M, Babiarz A, Bodys A, Uliński R, Żochowski M, Peller M, Scisło P, Kochanowski J, Filipiak KJ, Opolski G.
    Pol Arch Intern Med; 2017 Dec 22; 127(12):823-831. PubMed ID: 28972957
    [Abstract] [Full Text] [Related]

  • 5. Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation in the Era of Direct Oral Anticoagulants.
    Harada M, Koshikawa M, Motoike Y, Ichikawa T, Sugimoto K, Watanabe E, Ozaki Y.
    Circ J; 2018 Oct 25; 82(11):2715-2721. PubMed ID: 30101809
    [Abstract] [Full Text] [Related]

  • 6. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, Masoudi FA, Hess PL, Maddox TM, Ho PM.
    BMC Cardiovasc Disord; 2017 Sep 02; 17(1):236. PubMed ID: 28865440
    [Abstract] [Full Text] [Related]

  • 7. Transesophageal vs. intracardiac echocardiographic screening in patients undergoing atrial fibrillation ablation with uninterrupted rivaroxaban.
    Tsyganov A, Shapieva A, Sandrikov V, Fedulova S, Mironovich S, Dzeranova A, Lyan E.
    BMC Cardiovasc Disord; 2017 Jun 29; 17(1):171. PubMed ID: 28662693
    [Abstract] [Full Text] [Related]

  • 8. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC, Ahmad A, Petrini M, Tang W, Evans A, Rush T, Thompson D, Oh K, Schwartzman E.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):80-90. PubMed ID: 30500885
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
    Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ.
    Am J Med; 2016 Nov 01; 129(11):1198-1204. PubMed ID: 27341955
    [Abstract] [Full Text] [Related]

  • 10. Atrial Thrombosis Prevalence Before Cardioversion or Catheter Ablation of Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists.
    Troisi F, Guida P, Vitulano N, Quadrini F, Di Monaco A, Patti G, Grimaldi M.
    Am J Cardiol; 2024 May 01; 218():77-85. PubMed ID: 38458580
    [Abstract] [Full Text] [Related]

  • 11. Outcome of non-vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.
    Lin C, Quan J, Bao Y, Hua W, Ke M, Zhang N, Jin Q, Xie Y, Wei Y, Ling T, Pan W, Wu L, Xie Y.
    J Cardiovasc Electrophysiol; 2020 Mar 01; 31(3):658-663. PubMed ID: 31975470
    [Abstract] [Full Text] [Related]

  • 12. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
    Tscholl V, Lsharaf AK, Lin T, Bellmann B, Nagel P, Lenz K, Landmesser U, Roser M, Rillig A.
    Clin Cardiol; 2017 Nov 01; 40(11):1095-1099. PubMed ID: 28846806
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK, Sood NA, Bunz TJ, Coleman CI.
    J Am Heart Assoc; 2018 Apr 13; 7(8):. PubMed ID: 29654196
    [Abstract] [Full Text] [Related]

  • 14. Risk factors for thrombosis and spontaneous echocardiographic contrast with sludge in atrial fibrillation patients treated with oral anticoagulants before electrical cardioversion.
    Rekosz J, Karwowski J, Kowalik I, Wiktorska A, Wrzosek K, Solecki M, Szmarowska K, Szymańska A, Mierzejewska B, Syska-Sumińska J, Dłużniewski M.
    Kardiol Pol; 2024 Apr 13; 82(5):516-526. PubMed ID: 38606742
    [Abstract] [Full Text] [Related]

  • 15. Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes.
    Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Hirohata S, Kusachi S.
    J Cardiovasc Electrophysiol; 2019 Dec 13; 30(12):2823-2833. PubMed ID: 31701593
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation.
    Fleddermann A, Eckert R, Muskala P, Hayes C, Magalski A, Main ML.
    Am J Cardiol; 2019 Jan 01; 123(1):57-62. PubMed ID: 30376957
    [Abstract] [Full Text] [Related]

  • 17. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL, Sing CW, Lau WCY, Li GHY, Lip GYH, Tan KCB, Cheung BMY, Chan EWY, Wong ICK.
    Cardiovasc Diabetol; 2021 Mar 25; 20(1):71. PubMed ID: 33766030
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I, Zhang Y, Saba S.
    Am J Cardiol; 2017 Nov 15; 120(10):1813-1819. PubMed ID: 28864318
    [Abstract] [Full Text] [Related]

  • 19. Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry.
    Di Biase L, Briceno DF, Trivedi C, Mohanty S, Gianni C, Burkhardt JD, Mohanty P, Bai R, Gunda S, Horton R, Bailey S, Sanchez JE, Al-Ahmad A, Hranitzky P, Gallinghouse GJ, Reddy YM, Zagrodzky J, Hongo R, Beheiry S, Lakkireddy D, Natale A.
    Heart Rhythm; 2016 Jun 15; 13(6):1197-202. PubMed ID: 26994940
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
    Yoshimura A, Iriki Y, Ichiki H, Oketani N, Okui H, Maenosono R, Namino F, Miyata M, Ohishi M.
    J Cardiol; 2017 Jan 15; 69(1):228-235. PubMed ID: 27131792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.